百奥赛图-B获4.1亿美元授权 IDE034或成新抗癌药

财中社
Nov 11, 2024

财中社11月11日电百奥赛图-B(02315)发布自愿公告,宣布IDEAYA Biosciences, Inc.已行使选项,获得公司B7H3/PTK7拓扑异构酶抑制剂有效载荷双特异性抗体偶联药物IDE034的全球独家授权,并提名该项目为开发候选药物。根据双方协议,公司将获得总额达4.1亿美元的各项费用,其中包括最多1亿美元的临床开发和监管里程碑付款。IDE034预计在2025年向美国FDA提交新药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10